

# Justification Document for the Selection of a CoRAP Substance

**Substance Name (public name):** 1,3-dihydro-4(or 5)-methyl-2H-

benzimidazole-2-thione

**EC Number:** 258-904-8

**CAS Number:** 53988-10-6

Authority: DE MSCA

**Date:** 22/03/2016

#### Note

This document has been prepared by the evaluating Member State given in the CoRAP update

# **Table of Contents**

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	4
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	5
3 3	Classification  1.1 Harmonised Classification in Annex VI of the CLP  1.2 Self classification  1.3 Proposal for Harmonised Classification in Annex VI of the CLP	<b>5</b> 5 5
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	6
4.1	Tonnage and registration status	6
4.2	Overview of uses	6
	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE RAP SUBSTANCE	8
5.1	Legal basis for the proposal	8
	Selection criteria met (why the substance qualifies for being in AP)	8
5.3	Initial grounds for concern to be clarified under Substance Evaluatio	n 8
	Preliminary indication of information that may need to be requested larify the concern	9
5.5	Potential follow-up and link to risk management	9

### 1 IDENTITY OF THE SUBSTANCE

## 1.1 Other identifiers of the substance

**Table: Other Substance identifiers** 

EC name (public):	1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione
IUPAC name (public):	1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione
Index number in Annex VI of the CLP Regulation:	-
Molecular formula:	C <sub>8</sub> H <sub>8</sub> N <sub>2</sub> S
Molecular weight or molecular weight range:	164.2 g/mol
Synonyms:	Vulkanox MB2/MG

Type of substance	☐ Mono-constituent		□ UVCB
-------------------	--------------------	--	--------

### Structural formula:

## 1.2 Similar substances/grouping possibilities

\_

## **2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION**

**Table: Completed or ongoing processes** 

RMOA	☐ Risk Management Option Analysis (RMOA)					
	on	☐ Compliance check, Final decision				
	Evaluation	☐ Testing proposal (EC 262-872-0)				
sses	Ev	☐ CoRAP and Substance Evaluation				
REACH Processes	Authorisation	☐ Candidate List				
REAC	Author	☐ Annex XIV				
	G Strip ☐ Annex XVII1					
Harmonised C&L		☐ Annex VI (CLP) (see section 3.1)				
ses other tion		Plant Protection Products Regulation				
Processes under other EU legislation		Regulation (EC) No 1107/2009  Biocidal Product Regulation Regulation (EU) 528/2012 and amendments				
rious ation		☐ Dangerous substances Directive Directive 67/548/EEC (NONS)				
Previc legislat		☐ Existing Substances Regulation  Regulation 793/93/EEC (RAR/RRS)				
EP) holm ntion PS		☐ Assessment				
(UNEP) Stockholm convention (POPs Protocol)	☐ In relevant Annex					

<sup>&</sup>lt;sup>1</sup> Please specify the relevant entry.

Other processes / EU legislation	☐ Other (provide further details below)

TPE on reproductive toxicity (pre-natal developmental toxicity) testing is proposed with the substance 1,3-dihydro-4(or 5)-methyl-2H-benzimidazole-2-thione, zinc salt (CAS: 61617-00-3, EC: 262-872-0).

## 3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

#### 3.1 Classification

#### 3.1.1 Harmonised Classification in Annex VI of the CLP

No harmonised classification is available.

#### 3.1.2 Self classification

• In the registration:

Acute Tox. 4 H302, Acute Tox. 4 H332, Repr. 2 H361 (Oral), STOT RE 2 H373 (Oral), Aquatic Chronic 1 H410 M-factor = 1

 The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

Aquatic Chronic 3 H412

# 3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

Currently, no proposal for harmonized classification and labeling is available.

## 4 INFORMATION ON (AGGREGATED) TONNAGE AND USES<sup>2</sup>

## 4.1 Tonnage and registration status

**Table: Tonnage and registration status** 

From ECHA dissemination site							
	∑ Full registration(s) (Art. 10)     ☐ Intermediate registration(s) (Art. 17 and/or 18)						nd/or 18)
Tonnage band (a	Tonnage band (as per dissemination site)						
☐ 1 - 10 tpa			□ 10 -	100 tpa			000 tpa
□ 1000 - 10,00	00 tpa	ı	☐ 10,00	00 - 100,000	tpa	☐ 100,000 tpa	- 1,000,000
☐ 1,000,000 - tpa	10,00	0,000	☐ 10,00 tpa	☐ 10,000,000 - 100,000,000 tpa			00,000 tpa
☐ <1		. >+ tpa	e.g. 10+	; 100+ ; 10	,000+ tpa)	☐ Confider	ntial
Joint Submission	۱.						
The uses of the substance indicate a probable release of relevant amounts of the substance into the environment. There are article service life uses with wide dispersive outdoor use.  Table: Uses.  Part 1:							
Part 2:					Use(s)		
Uses as intermediate	-						
Formulation							
		cion of tyres, rubber and plastic goods. Industrial use of process ors for polymerisation processes in production of resins, rubbers, rs.					
Uses by professional workers							

EC no 258-904-8 MSCA - DE Page 6 of 10

 $<sup>^{2}</sup>$  Data taken from ECHA dissemination site (accessed in May 2015)

### JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE

Consumer Uses	
	Production of tyres, rubber and plastic goods. Environmental exposure may be expected during article service life.
Article service life	AC 1: Vehicles AC 2: Machinery, mechanical appliances, electrical/electronic articles AC 3: Electrical batteries and accumulators AC 10: Rubber articles AC 13: Plastic articles
Use advised against	

\_\_\_\_\_

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE						
5.1. Legal basis for the proposal						
☐ Article 44(2) (refined	d prioritisation criteria for subs	stance evaluation)				
☐ Article 45(5) (Memb	er State priority)					
5.2. Selection criteria m	et (why the substance qua	alifies for being in CoRAP)				
☐ Fulfils criteria as CMR/ Suspe	ected CMR					
☐ Fulfils criteria as Sensitiser/	Suspected sensitiser					
$oxed{\boxtimes}$ Fulfils criteria as potential er	docrine disrupter					
☐ Fulfils criteria as PBT/vPvB /	Suspected PBT/vPvB					
☐ Fulfils criteria high (aggregat	ted) tonnage ( $tpa > 1000$ )					
$oxed{\boxtimes}$ Fulfils exposure criteria						
☐ Fulfils MS's (national) prioriti	es					
5.3 Initial grounds for c	oncern to be clarified	under Substance Evaluation				
Hazard based concerns						
CMR C M R	Suspected CMK					
☐ Sensitiser ☐ Suspected Sensitiser³						
☐ PBT/vPvB ☐ Suspected PBT/vPvB¹ ☐ Other (please specify below)						
Exposure/risk based concerns						
☐ Wide dispersive use ☐ Consumer use ☐ Exposure of sensitive populations						
	·					
☐ High RCR	☐ High RCR ☐ High (aggregated) ☐ Other (please specify below)					

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

CMR/Sensitiser: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory)

Suspected CMR/Suspected sensitiser: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)

#### ED concern:

The substance gives evidence for being an endocrine disruptor for the environment. Because of structural characteristics the substances can interact with the hypothalamus-pituitary-thyroid axis, since they also belong to the group of thioamides where most of the thyroid disruptors are found (e.g. Methimazole, Phenylthiourea, Propylthiouracil, Mercaptoimidazole). This group of chemicals interacts on the one hand with the thyroid-peroxidase-enzym (which has an important role in the thyroid hormonsynthesis) and on the other it can block the dejodinase-enzym (which is in charge for the conversion of T4 to T3). It is not yet clearly proven, if these substances really cause such effects.

According to the publications of (Kawasaki et al., 1998; Sakemi et al., 2002) the substance has a lower thyroid disruption potential than MBI (a clear thyroid disruptor). (Kawasaki et al., 1998; Sakemi et al., 2002) conducted an in vitro test (lactoperoxidase-LPX assay) and a two-week repeated oral administration toxicity study with male rats. There is a clear hint from the papers that the substance is thyroid active.

The substance is not readily biodegradable, indicating that it has the potential to persist in the environment. There is no test on bioaccumulation (in the registration dossier) available. The log  $K_{ow}$  is 0.3 to 0.4 according to the registration dossier.

Due to the registered uses of the substance which point towards a wide dispersive use, significant environmental exposure has to be assumed. Therefore, the potential risk of endocrine disruptive properties in the environment has to be clarified.

# 5.4 Preliminary indication of information that may need to be requested

clarify the conce	rn			,			
☐ Information on toxicological properties ☐ Information on physico-chemical propert							
☐ Information on fate and behaviour ☐ Information on exposure							
☐ Information on ecotoxicological properties ☐ Information on uses							
	☑ Information ED potential ☐ Other (provide further details below)						
It is necessary to examine the endocrine disrupting properties of the substance and the effects on the environment. For this reason information from a non-standard ED-relevant test might be required as there is no in vivo study available to conclude for the environment on the apical effects on organisms.  An Amphibian metamorphosis assay (AMA – OECD 231) (Tier 1), a Larval Amphibian Growth and Development Assay (LAGDA) (Tier 2) or another test might be suitable to provide the required information.							
5.5 Potential follow-up and link to risk management							
☐ Harmonised C&L	☐ Harmonised C&L ☐ Restriction ☐ Authorisation details) (ED-concern)						
	If the ED-concern is substantiated a SVHC-identification according to art. 57 f might be proposed and an analysis of risk management options would be undertaken to identify the most adequate regulatory action.						

EC no 258-904-8 MSCA - DE Page 9 of 10

### References:

Kawasaki, Y., Umemura, T., Saito, M., Momma, J., Matsushima, Y., Sekiguchi, H., Matsumoto, M., Sakemi, K., Isama, K., Inoue, T., Kurokawa, Y., Tsuda, M., 1998. Toxicity study of a rubber antioxidant, 2-mercaptobenzimidazole, by repeated oral administration to rats. The Journal of toxicological sciences 23, 53-68.

Sakemi, K., Ito, R., Umemura, T., Ohno, Y., Tsuda, M., 2002. Comparative toxicokinetic/toxicodynamic study of rubber antioxidants, 2-mercaptobenzimidazole and its methyl substituted derivatives, by repeated oral administration in rats. Arch Toxicol 76, 682-691.